Search Result

Results for "

JAK2/ACVR1 (ALK2)/ALK5 inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Ack1 (1) Akt (3) AMPK (3) Anaplastic lymphoma kinase (ALK) (17) Apoptosis (57) Arginase (1) Atg8/LC3 (3) Aurora Kinase (7) Autophagy (24) Bacterial (3) Bcl-2 Family (2) Bcr-Abl (6) Biochemical Assay Reagents (1) Btk (2) c-Kit (1) Casein Kinase (1) Caspase (3) CDK (7) Checkpoint Kinase (Chk) (1) COX (4) Cytochrome P450 (3) Deubiquitinase (2) Drug Derivative (1) Drug Intermediate (1) E3 Ligase Ligand-Linker Conjugates (1) EGFR (4) Endogenous Metabolite (4) Epigenetic Reader Domain (2) ERK (4) FGFR (1) FLT3 (27) GSK-3 (4) HDAC (4) HIV (3) IKK (3) Interleukin Related (13) IRAK (1) Isotope-Labeled Compounds (6) Itk (1) JAK (237) JNK (1) Keap1-Nrf2 (1) Ligands for Target Protein for PROTAC (1) LRRK2 (1) MEK (2) MHC (1) Microtubule/Tubulin (1) Mitosis (2) MMP (1) Monoamine Oxidase (2) mRNA (3) mTOR (4) Na+/K+ ATPase (1) nAChR (2) NADH Dehydrogenase (1) NF-κB (6) NO Synthase (6) Organoid (14) Orthopoxvirus (1) p38 MAPK (5) p62 (3) Parasite (1) PARP (1) PERK (1) PI3K (5) Pim (1) PKC (1) Polo-like Kinase (PLK) (3) PROTACs (7) Protease Activated Receptor (PAR) (1) Proteasome (1) Reactive Oxygen Species (ROS) (4) Reference Standards (19) RET (3) RIP kinase (3) Small Interfering RNA (siRNA) (12) Src (2) STAT (48) Syk (8) TGF-beta/Smad (12) TGF-β Receptor (82) Thrombin (1) Thrombopoietin Receptor (2) TNF Receptor (7) Toll-like Receptor (TLR) (2) Trk Receptor (2) VEGFR (2) Virus Protease (1)
By Research Areas:	Cancer (247) Cardiovascular Disease (16) Endocrinology (1) Infection (8) Inflammation/Immunology (117) Metabolic Disease (15) Neurological Disease (5)
Click Chemistry:	Alkynes (1)
Oligonucleotides:	Rat Pre-designed siRNA Sets (4) mRNA (3) Mouse Pre-designed siRNA Sets (4) Human Pre-designed siRNA Sets (4) siRNAs (12)

374

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Oligonucleotides

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-109179A

Itacnosertib hydrochloride TP-0184 hydrochloride	JAK Anaplastic lymphoma kinase (ALK) FLT3 STAT PI3K Akt mTOR TGF-beta/Smad TGF-β Receptor	Cancer
Itacnosertib hydrochloride (TP-0184 hydrochloride) is the inhibitor for FLT3, *ACVR1* (ALK2, IC₅₀=8 nM) and *JAK2* (IC₅₀=8540 nM). Itacnosertib hydrochloride exhibits anti-leukemic activity ^[1] ^[2].

HY-109179

Itacnosertib TP-0184	JAK Anaplastic lymphoma kinase (ALK) FLT3 STAT PI3K Akt mTOR TGF-beta/Smad TGF-β Receptor	Cancer
Itacnosertib (TP-0184) is the inhibitor for FLT3, *ACVR1* (ALK2, IC₅₀=8 nM) and *JAK2* (IC₅₀=8540 nM). Itacnosertib exhibits anti-leukemic activity ^[1] ^[2].

HY-102055

JAK2 JH2 Tracer 5+ Cited Publications	JAK	Others
JAK2 JH2 Tracer (Tracer 5) is a fluorescent probe for **JAK2 JH2 domain, with a K_d** value of 0.2 μM ^[1] ^[2].

HY-174786

*Human ACVR1* mRNA**	mRNA	Cancer
Human ACVR1 mRNA encodes the human activin A receptor type 1 (ACVR1) protein, a member of type I receptor which signals a particular transcriptional response in concert with activin type II receptors.

HY-RS00238

Acvr1 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Acvr1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Acvr1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Acvr1 Rat Pre-designed siRNA Set A Acvr1 Rat Pre-designed siRNA Set A

HY-RS00236

ACVR1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
ACVR1 Human Pre-designed siRNA Set A contains three designed siRNAs for ACVR1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

ACVR1 Human Pre-designed siRNA Set A ACVR1 Human Pre-designed siRNA Set A

HY-RS00237

Acvr1 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Acvr1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Acvr1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Acvr1 Mouse Pre-designed siRNA Set A Acvr1 Mouse Pre-designed siRNA Set A

HY-151273

ALK5-IN-27	TGF-β Receptor	Cancer
ALK5-IN-27 (Compound EX-04) is a potent *ALK-5* inhibitor with an IC₅₀ ≤10 nM. ALK5-IN-27 also inhibits *ALK-2* (selectivity ALK2/ALK5 ≤10) ^[1].

HY-151270

ALK5-IN-25	TGF-β Receptor	Cancer
ALK5-IN-25 (compound EX-02) is a potent *ALK-5* inhibitor with an IC₅₀ ≤10 nM.ALK5-IN-25 also inhibits *ALK-2* (selectivity ALK2/ALK5≤10). ALK5-IN-25 can be used for the research of cancer ^[1].

HY-174428

*PROTAC JAK2* degrader-1**	JAK STAT PROTACs	Cancer
PROTAC JAK2 degrader-1 (Compound 10i) is a *JAK2* PROTAC degrader with a DC₅₀ of 27.35 nM for JAK2 V617F. PROTAC JAK2 degrader-1 promotes the ubiquitination and degradation of *JAK2. PROTAC JAK2* degrader-1 inhibits the phosphorylation of *JAK2, STAT3* and *STAT5. PROTAC JAK2* degrader-1 can be used in the research of myeloproliferative neoplasms (Pink: JAK2 ligand (HY-174430); Blue: E3 ligase ligand (HY-W087383); Black: E3 ligase ligand + linker (HY-174432)) ^[1].

HY-112815

ALK2-IN-2 1 Publications Verification	TGF-β Receptor	Cardiovascular Disease Inflammation/Immunology
ALK2-IN-2 is an orally active and selective inhibitor of *ALK2* (ACVR1), with an IC₅₀ value of 9 nM, and over 700-fold selectivity against ALK3. ALK2-IN-2 can inhibit oxidative stress and protect endothelial cells ^[1] ^[2].

HY-146186

JAK2 JH2 binder-1	JAK	Cancer
JAK2 JH2 binder-1 (compound 11) is a potent and selective **JAK2 JH2 binder, with a K_d** of 37.1 nM. JAK2 JH2 binder-1 has the potential for various myeloproliferative neoplasms research ^[1].

HY-15480

NSC 42834 2 Publications Verification JAK2 inhibitor V; Z3	JAK	Cancer
NSC 42834 (JAK2 Inhibitor V), a novel specific inhibitor of *Jak2, inhibits Jak2-V617F and Jak2*-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity.

HY-RS07020

Jak2 Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA) JAK	Others
Jak2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Jak2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Jak2 Rat Pre-designed siRNA Set A Jak2 Rat Pre-designed siRNA Set A

HY-RS07018

JAK2 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA) JAK	Others
JAK2 Human Pre-designed siRNA Set A contains three designed siRNAs for JAK2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

JAK2 Human Pre-designed siRNA Set A JAK2 Human Pre-designed siRNA Set A

HY-RS07019

Jak2 Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA) JAK	Others
Jak2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Jak2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Jak2 Mouse Pre-designed siRNA Set A Jak2 Mouse Pre-designed siRNA Set A

HY-161662

ALK5-IN-80	TGF-β Receptor	Cancer
ALK5-IN-80 (Compound 29b) is a selective *ALK5* inhibitor with an IC₅₀ value of 3.7 nM. ALK5-IN-80 can be used for cancer research ^[1].

HY-144043

ALK5-IN-8	TGF-β Receptor	Cancer
ALK5-IN-8 is a potent inhibitor of TGFβRI (ALK5). ALK5-IN-8 Inhibits the phosphorylation of ALK5 on its downstream signaling proteins (Smad2 or Smad3) by blocking the binding of TGFβRI to ligands, thereby affecting or blocking TGF-β signaling. ALK5-IN-8 has the potential for the research of various ALK5-mediated related diseases (extracted from patent WO2021190425A1, compound 1) ^[1].

HY-144437

ALK5-IN-9	TGF-β Receptor	Cancer
ALK5-IN-9 (Compound 8h) is a potent and orally active inhibitor of TGFβRI (ALK5). ALK5-IN-9 inhibits ALK5 autophosphorylation and NIH3T3 cell activity with IC₅₀ values of 25 nM and 74.6 nM, respectively. ALK5-IN-9 also shows favorable pharmacokinetic profile and ameliorated hERG inhibition. ALK5-IN-9 has the potential for the research of cancer disease ^[1].

HY-151289

ALK5-IN-34	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-34 is an selective orally active activin receptor-like kinase (ALK) inhibitor. ALK5-IN-34 can inhibit the activity of ALK5-IN-34 with an IC₅₀ value of ≤10 nM. ALK5-IN-34 also has inhibitory of tumor growth and can be used for the research of proliferative diseases, such as cancer ^[1].

HY-P1590

*Tyrosine Protein Kinase JAK 2* (Phospho-Tyr8, 9)**	JAK	Inflammation/Immunology Cancer
Tyrosine Protein Kinase JAK 2 (Phospho-Tyr8, 9) is a peptide corresponding to amino acids 475 to 491 of mouse JAK2.

HY-151277

ALK5-IN-29	Anaplastic lymphoma kinase (ALK)	Cancer
ALK5-IN-29 is an selective activin receptor-like kinase (ALK) inhibitor. ALK5-IN-29 can inhibit the activity of ALK5 with an IC₅₀ value of ≤10 nM. ALK5-IN-29 also has inhibitory of tumor growth and can be used for the research of proliferative diseases, such as cancer ^[1].

HY-W064657

Momelotinib dihydrochloride	JAK	Others
Momelotinib (dihydrochloride) is a *JAK1/JAK2* inhibitor that also antagonizes *ACVR1, leading to downregulation of Hepcidin* expression and increased availability of iron for erythropoiesis. Momelotinib (dihydrochloride) can reduce transfusion burden and spleen enlargement caused by myelofibrosis, showing potential value in research and application within the field of myelofibrosis ^[1].

HY-117887

Fidrisertib BLU-782; IPN-60130; ALK2-IN-1	TGF-β Receptor	Cancer
Fidrisertib (BLU-782) is the orally active inhibitor for activin receptor-like kinase 2 (ALK2) that inhibits ALK2 ^R206H, *ALK2, ALK1, ALK6, ALK3, ALK4, TGFβR2* and *ALK5* with IC₅₀s of 0.2, 0.6, 3, 24, 45, 65, 67 and 155 nM, respectively ^[1] ^[2].

HY-162902

ALK5-IN-82	TGF-β Receptor	Cardiovascular Disease
ALK5-IN-82 is a potent and selective inhibitor against activin receptor-like kinase 5 (ALK5) with an IC₅₀ value of 9.1 nM. ALK5-IN-82 inhibits the protein expression of α-smooth muscle actin (α-SMA), collagen I and tissue inhibitor of metalloproteinase 1 (TIMP-1)/matrix metalloproteinase 13 (MMP-13) in transforming growth factor-β-induced human umbilical vein endothelial cells. ALK5-IN-82 is promising for research of cardiac fibrosis ^[1].

HY-163507

ALK5-IN-79	Anaplastic lymphoma kinase (ALK)	Cancer
ALK5-IN-79 (compound 57) is an *ALK* inhibitor with anticancer activity, by blocking *TGF-β1/SMAD* signaling pathway. ALK5-IN-79 attenuates the production of extracellular matrix (ECM) and deposition of collagen. ALK5-IN-79 exhibits adequate pharmacokinetic (PK) properties and good in vivo tolerance.

HY-159952

ALK5-IN-84	Anaplastic lymphoma kinase (ALK)	Cardiovascular Disease Neurological Disease Inflammation/Immunology Cancer
ALK5-IN-84 (Compound 23) is an ALK5 inhibitor with a pK_i value of 9.35 against *hALK5. When administered via inhalation, ALK5-IN-84 exhibits significant ALK5* inhibitory activity. ALK5-IN-84 is promising for the development of inhaled *ALK5* inhibitors ^[1].

HY-P990022

Prafnosbart DS-6016A	TGF-β Receptor	Metabolic Disease
Prafnosbart (DS-6016A) is an IgG1-kappa, anti-ACVR1 (activin A receptor type 1, ACVRLK2, ALK2, ACVR1A, SKR1) humanized monoclonal antibody. Prafnosbart can be used for bone metabolism disorders research ^[1].

HY-142949

ALK5-IN-7	TGF-β Receptor	Inflammation/Immunology Cancer
ALK5-IN-7 is a potent inhibitor of *ALK5. Transforming growth factor beta (TGF-β) is a multifunctional cytokine that is involved in regulating cell proliferation, differentiation and apoptosis through complex receptor signaling pathways on the cell surface in an autocrine, paracrine and endocrine manner. ALK5*-IN-7 has the potential for the research of TGF-β-related diseases and conditions, including but not limited to tumors, fibrotic diseases, inflammatory diseases, autoimmune diseases, etc (extracted from patent WO2021129621A1, compound 4) ^[1].

HY-142950

ALK5-IN-6	TGF-β Receptor	Inflammation/Immunology Cancer
ALK5-IN-6 is a potent inhibitor of *ALK5. Transforming growth factor beta (TGF-β) is a multifunctional cytokine that is involved in regulating cell proliferation, differentiation and apoptosis through complex receptor signaling pathways on the cell surface in an autocrine, paracrine and endocrine manner. ALK5*-IN-6 has the potential for the research of TGF-β-related diseases and conditions, including but not limited to tumors, fibrotic diseases, inflammatory diseases, autoimmune diseases, etc (extracted from patent WO2021129621A1, compound 1) ^[1].

HY-155746

JAK2-IN-9	JAK	Infection Inflammation/Immunology
JAK2-IN-9 (Compound A8) is a selective *JAK2* inhibitor (IC₅₀: 5 nM). JAK2-IN-9 inhibits the phosphorylation of JAK2, STAT3, and STAT5. JAK2-IN-9 has metabolic stabilities. JAK2-IN-9 induces apoptosis. JAK2-IN-9 can be used for research of myeloproliferative neoplasms (MPNs) ^[1].

HY-151272

ALK5-IN-26	Anaplastic lymphoma kinase (ALK)	Cancer
ALK5-IN-26 (EX-22) is an *ALK* (Activin receptor-like kinase) inhibitor. ALK5-IN-26 inhibits ALK5 with an IC₅₀ value ≤10 nM. ALK5-IN-26 can be used for the research of cancer ^[1].

HY-169326S

JAK2-IN-11	Isotope-Labeled Compounds JAK	Cancer
JAK2-IN-11 (Example 6) is a *JAK2* kinase inhibitor with IC₅₀ ≤10 nM against JH2 BIND WT/V617F. JAK2-IN-11 has antitumor activity ^[1].

HY-161684

JAK2-IN-10	JAK	Cancer
JAK2-IN-10 (compound 5) is a potent JAK2 V617F inhibitor with an IC₅₀ value of ≤10 nM ^[1].

HY-151233

ALK5-IN-10	TGF-β Receptor	Cancer
ALK5-IN-10 (Compound 5d) is a TGF-β type I receptor kinase *ALK5* inhibitor, with IC₅₀s of 0.007 and 1.98 μM for ALK5 and p38α, respectively. ALK5-IN-10 can be used for the research of cancer ^[1].

HY-137756

JAK2-IN-6 1 Publications Verification	JAK	Cancer
JAK2-IN-6, a multiple-substituted aminothiazole derivative, is a potent and selective *JAK2* inhibitor with an IC₅₀ of 22.86 μg/mL. JAK2-IN-6 shows no activity against JAK1 and JAK3. JAK2-IN-6 has anti-proliferative effect against cancer cells ^[1].

HY-151281

ALK5-IN-31	TGF-β Receptor	Cancer
ALK5-IN-31 (compound Ex-08) is a selective *ALK-5* inhibitor (IC₅₀≤10 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-31 has the potential to inhibit growth of tumour in vivo. ALK5-IN-31 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis ^[1].

HY-151275

ALK5-IN-28	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-28 (compound Ex-05) is a selective *ALK-5* inhibitor (IC₅₀≤10 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-28 has the potential to inhibit growth of tumour in vivo. ALK5-IN-28 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis ^[1].

HY-151283

ALK5-IN-33	TGF-β Receptor	Cancer
ALK5-IN-33 (Compound EX-10) is a selective, orally active *ALK-5* inhibitor with an IC₅₀ ≤10 nM ^[1].

HY-151282

ALK5-IN-32	TGF-β Receptor TGF-beta/Smad	Cancer
ALK5-IN-32 (compound EX-09) is a selective *ALK-5* inhibitor (10 nM<IC₅₀<100 nM), inhibits TGF-β-induced SMAD signaling. ALK5-IN-32 has the potential to inhibit growth of tumour in vivo. ALK5-IN-32 can be used in study of proliferative diseases such as cancer, fibrotic diseases, and systemic sclerosis ^[1].

HY-168607

ALK5-IN-83	TGF-beta/Smad	Cancer
ALK5-IN-83 (compound 13b) is a *ALK5* inhibitor with the IC₅₀ of 0.13 μM. ALK5-IN-83 inhibits TGF-β1-induced Smad2 phosphorylation and cell motility in A549 cells ^[1].

HY-161967

JAK2/FLT3-IN-3	FLT3 JAK Apoptosis	Cancer
JAK2/FLT3-IN-3 (11r) is a dual FLT3 and *JAK2* inhibitor, with IC₅₀ values of 2.01 nM, 0.51 nM and 104.40 nM for JAK2, FLT3 and JAK3, respectively. JAK2/FLT3-IN-3 (11r) induces apoptosis and possesses antitumor activity ^[1].

HY-151279

ALK5-IN-30	Anaplastic lymphoma kinase (ALK)	Cancer
ALK5-IN-30 (EX-07) is a potent *ALK* inhibitor, inhibits *ALK5* and TGFβ-R1 with both IC₅₀s <10 nM ^[1].

HY-167864

M4K2308	TGF-β Receptor	Cancer
M4K2308 is a selective ether-linked inhibitor of *ALK2* with an IC₅₀ of 2 nM. M4K2308 exhibits exceptional selectivity for ALK2 over ALK5 (IC₅₀ of 224 nM). M4K2308 has the potential for the study of diffuse intrinsic pontine glioma (DIPG) research ^[1].

HY-143884

JAK2/TYK2-IN-1	JAK	Inflammation/Immunology
JAK2/TYK2-IN-2 is a potent and selective *TYK2* inhibitor with IC₅₀ values of 9 and 157 nM for *TYK2* and *JAK2, respectively. JAK2*/TYK2-IN-2 has anti-inflammatory activity ^[1].

HY-112877

ALK-5-IN-1	TGF-β Receptor	Cancer
ALK-5-IN-1 is an *ALK-5* inhibitor. ALK-5-IN-1 can be used for the research of cancer, and conditions involving fibrosis ^[1].

HY-173149

CDD-2789	Anaplastic lymphoma kinase (ALK) TGF-beta/Smad TGF-β Receptor	Cancer
CDD-2789 is a highly selective small-molecule inhibitor targeting Activin receptor type 1 (ALK2, also known as *ACVR1). It blocks the SMAD1/5* signaling pathway mediated by *ALK2/ALK1, thereby effectively suppressing downstream phosphorylation events induced by BMP* and activin A. In the NanoBRET cellular model, CDD-2789 exhibits an inhibitory IC₅₀ of 0.54 µM against *ALK2. CDD-2789 holds promise for research on ALK2*-related diseases, including diffuse intrinsic pontine glioma (DIPG), ependymoma, endometrial cancer, melanoma, non–small cell lung cancer, colorectal cancer, and pancreatic cancer ^[1].

HY-12071A

LDN193189 Tetrahydrochloride 70+ Cited Publications DM-3189 Tetrahydrochloride	Organoid TGF-β Receptor	Cancer
LDN193189 Tetrahydrochloride is a selective BMP type I receptor inhibitor, which efficiently inhibits *ALK2* and *ALK3* (IC₅₀=5 nM and 30 nM, respectively), with weaker effects on ALK4, ALK5 and ALK7 (IC₅₀≥500 nM) ^[1].

HY-176479

JAK2-IN-12	JAK	Cancer
JAK2-IN-12 (compound 23) is a *JAK2* inhibitor with a pIC₅₀ of 8.2. JAK2-IN-12 can be used for study of myelofibrosi ^[1].

HY-174988

JAK2-IN-13	JAK STAT	Cancer
JAK2-IN-13 is a potent and orally active *JAK2* inhibitor with an IC₅₀ of 54.7 nM. JAK2-IN-13 downregulates the expressions of p-STAT3 and *p-STAT5. JAK2-IN-13 exhibits good bioavailability and potent inhibition of rhEPO-induced extramedullary erythropoiesis and polycythemia vera. JAK2*-IN-13 can be used for the study of myeloproliferative neoplasms ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N1356

Reticuline 1 Publications Verification	Cardiovascular Disease Alkaloids Structural Classification Classification of Application Fields Source classification Phenols Polyphenols Plants Lauraceae Isoquinoline Alkaloids Lindera aggregata (Sims) Kosterm. Disease Research Fields	JAK STAT NF-κB Endogenous Metabolite
Reticuline shows anti-inflammatory effects through *JAK2/STAT3* and NF-κB signaling pathways. Reticuline inhibits mRNA expressions of TNF-α, and IL-6 and reduces the phosphorylation levels of JAK2 and STAT3 ^[1]. Reticuline exhibits cardiovascular effects ^[2].

HY-113573

Protosappanin A PTA	Structural Classification Classification of Application Fields Leguminosae Caesalpinia sappan L. Source classification Phenols Polyphenols Plants Inflammation/Immunology Disease Research Fields	Interleukin Related JAK STAT
Protosappanin A (PTA), an immunosuppressive ingredient and major biphenyl compound isolated from Caesalpinia sappan L, suppresses *JAK2/STAT3*-dependent inflammation pathway through down-regulating the phosphorylation of JAK2 and STAT3 ^[1].

HY-N1405

Cucurbitacin I 10+ Cited Publications Elatericin B; JSI-124; NSC-521777	Triterpenes Structural Classification Classification of Application Fields Terpenoids Cucurbitaceae Plants Disease Research Fields Lagenaria siceraria (Molina) Standl. Cancer	STAT JAK
Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-N1535

Ponicidin 4 Publications Verification Rubescensine B	Structural Classification other families Classification of Application Fields Terpenoids Labiatae Source classification Diterpenoids Emilia sonchifolia (L.) DC. Plants Inflammation/Immunology Disease Research Fields	Apoptosis
Ponicidin (Rubescensine B) is a diterpenoid derived from Rabdosia rubescens, and exhibits immunoregulatory, anti-inflammatory, anti-viral and anti-cancer activity. Ponicidin (Rubescensine B) induces apoptosis of gastric carcinoma cell, decreases the phosphorylation of JAK2 and STAT3, and shows no effect on protein levels of JAK2 and STAT3 ^[1].

HY-N0635

Prim-O-glucosylcimifugin 4 Publications Verification	Structural Classification Natural Products Ophryosporus axilliflorus Hieron. Classification of Application Fields Source classification Umbelliferae Plants Inflammation/Immunology Disease Research Fields	TNF Receptor NO Synthase COX
Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and *COX-2* expression by through regulating JAK2/STAT3 signaling.

HY-N4107

Phyllanthin 1 Publications Verification	Phyllanthus urinaria Linn. Structural Classification Classification of Application Fields Source classification Lignans Metabolic Disease Euphorbiaceae Phenylpropanoids Plants Disease Research Fields	TGF-beta/Smad
Phyllanthin is an effective oral anticancer agent. Phyllanthin inhibits MOLT-4 cell viability, increases apoptosis, inhibits cell migration and invasion. Phyllanthin exerts anti-fibrotic effects by down-regulating TGF signaling pathway via ALK5 and Smad2/3. Phyllanthin also has anti-inflammatory and antibacterial properties ^[1] ^[2] .

HY-N7452

Coumermycin A1 Maximum Cited Publications 16 Publications Verification	Structural Classification Microorganisms Antibiotics Source classification	JAK Bacterial Orthopoxvirus
Coumermycin A1 is a JAK2 signal activator. Coumermycin A1 inhibits DNA Gyrase which thereby inhibits cell division in bacteria. Coumermycin A1 shows anti-orthopoxvirus activity.

HY-N1405R

Cucurbitacin I (Standard) Elatericin B (Standard); JSI-124 (Standard); NSC-521777 (Standard)	Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Cucurbitaceae Plants Disease Research Fields Lagenaria siceraria (Molina) Standl. Cancer	STAT JAK Reference Standards
Cucurbitacin I (Standard) is the analytical standard of Cucurbitacin I. This product is intended for research and analytical applications. Cucurbitacin I is a natural selective inhibitor of *JAK2/STAT3*, with potent anti-cancer activity.

HY-N13294

Cernuumolide J TMJ-105	Structural Classification Terpenoids Carpesium cernuum L. Sesquiterpenes Source classification Plants Compositae	Apoptosis JAK STAT p38 MAPK JNK ERK
Cernuumolide J (TMJ-105) is an *JAK2/STAT3* inhibitor. Cernuumolide J induces G2/M phase arrest and apoptosis in HEL leukemia cells by downregulating the phosphorylation of *JAK2, STAT3, and Erk, and activating the phosphorylation of JNK* and p38 MAPK. Cernuumolide J inhibits HEL leukemia cell growth in a time- and concentration-dependent manner, with an IC₅₀ value of 1.79 μM. Cernuumolide J can be used for research in the field of anti-cancer therapy ^[1].

HY-N0635R

Prim-O-glucosylcimifugin (Standard)	Structural Classification Natural Products Ophryosporus axilliflorus Hieron. Source classification Umbelliferae Plants	TNF Receptor Reference Standards NO Synthase COX
Prim-O-glucosylcimifugin (Standard) is the analytical standard of Prim-O-glucosylcimifugin. This product is intended for research and analytical applications. Prim-O-glucosylcimifugin exerts anti-inflammatory effects through the inhibition of iNOS and COX-2 expression by through regulating JAK2/STAT3 signaling.

HY-121471

Chrysoeriol 2 Publications Verification	Structural Classification Classification of Application Fields Flavones Metabolic Disease Plants Phyllanthus Flavonoids Phenols Polyphenols Euphorbiaceae Brassicaceae Disease Research Fields Coronopus didymus	Endogenous Metabolite
Chrysoeriol is a kind of natural yellow ash, which can be used for heating plants Coronopus didymus. Chrysoeriol suppresses the JAK2/STAT3, IκB/p65, and NF-κB pathways, and has strong anti-inflammatory activity ^[1] ^[2] .

HY-N2963

Broussonin E	Structural Classification Thymelaeaceae Source classification Daphne giraldii Nitsche Phenols Polyphenols Plants	ERK p38 MAPK JAK STAT TNF Receptor Interleukin Related COX Arginase
Broussonin E is a phenolic compound and shows anti-inflammatory activity. Broussonin E can suppress inflammation by modulating macrophages activation statevia inhibiting the ERK and p38 MAPK and enhancing *JAK2-STAT3* signaling pathway. Broussonin E can be used for the research of inflammation-related diseases such as atherosclerosis ^[1].

HY-N4107R

Phyllanthin (Standard)	Phyllanthus urinaria Linn. Structural Classification Source classification Lignans Euphorbiaceae Phenylpropanoids Plants	Reference Standards TGF-beta/Smad
Phyllanthin (Standard) is the analytical standard of Phyllanthin. This product is intended for research and analytical applications. Phyllanthin is an effective oral anticancer agent. Phyllanthin inhibits MOLT-4 cell viability, increases apoptosis, inhibits cell migration and invasion. Phyllanthin exerts anti-fibrotic effects by down-regulating TGF signaling pathway via ALK5 and Smad2/3. Phyllanthin also has anti-inflammatory and antibacterial properties ^[1] ^[2] .

HY-N15564

Theleganbanin B	Structural Classification Microorganisms Source classification Phenols Polyphenols	Drug Derivative
Theleganbanin B is a p-terphenyl derivative found in the Thelephora ganbajun. Theleganbanin B inhibits TNF-α, IL-6, and IL-1β production in LPS-induced BV-2 microglial cells. Theleganbanin B inhibits the phosphorylation of JAK2/STAT3. Theleganbanin B is promising for research of neurodegenerative diseases ^[1].

HY-121471R

Chrysoeriol (Standard)	Structural Classification Flavonoids Flavones Phenols Polyphenols Euphorbiaceae Plants Brassicaceae Phyllanthus Coronopus didymus	Reference Standards Endogenous Metabolite
Chrysoeriol (Standard) is the analytical standard of Chrysoeriol. This product is intended for research and analytical applications. Chrysoeriol is a kind of natural yellow ash, which can be used for heating plants Coronopus didymus. Chrysoeriol suppresses the JAK2/STAT3, IκB/p65, and NF-κB pathways, and has strong anti-inflammatory activity ^[1] ^[2] .

HY-N0678

Icaritin 5 Publications Verification Anhydroicaritin	Flavonols Structural Classification Classification of Application Fields Source classification Plants Endogenous metabolite Human Gut Microbiota Metabolites Flavonoids Phenols Polyphenols Epimedium brevicornu Maxim. Berberidaceae Disease Research Fields Cancer	JAK Autophagy Apoptosis
Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 µM) and primary CML cells (IC₅₀ of 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis ^[1] ^[2] ^[3.

HY-N0918

Desmethoxyyangonin Demethoxyyangonin; 5,6-Dehydrokavain	Structural Classification other families Classification of Application Fields Source classification Other Diseases Other Phenylpropanoids Phenylpropanoids Plants Disease Research Fields	Monoamine Oxidase JAK IKK STAT NO Synthase Cytochrome P450
Desmethoxyyangonin is one of the six major kavalactones found in the Piper methysticum (kava) plant. Desmethoxyyangonin is a selective inhibitor of monoamine oxidase-B (MAO-B) (IC₅₀: 0.123 µM). Desmethoxyyangonin exerts anti-inflammatory effects by inhibiting Jak2/STAT3 and IKK signaling pathways. Desmethoxyyangonin induces CYP3A23 expression and leads to skeletal muscle relaxation ^[1] ^[2] .

HY-N0201

Atractylenolide I 5 Publications Verification	Structural Classification Classification of Application Fields Terpenoids Sesquiterpenes Source classification Astragalus caprinus L. Plants Compositae Disease Research Fields Cancer	TNF Receptor Toll-like Receptor (TLR) JAK STAT
Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated *JAK2* and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.

HY-N0918R

Desmethoxyyangonin (Standard) Demethoxyyangonin (Standard); 5,6-Dehydrokavain (Standard)	Structural Classification other families Source classification Other Phenylpropanoids Phenylpropanoids Plants	Reference Standards Monoamine Oxidase JAK STAT NO Synthase IKK Cytochrome P450
Desmethoxyyangonin (Standard) is one of the six major kavalactones found in the Piper methysticum (kava) plant. Desmethoxyyangonin (Standard) is a selective inhibitor of monoamine oxidase-B (MAO-B) (IC₅₀: 0.123 µM). Desmethoxyyangonin (Standard) exerts anti-inflammatory effects by inhibiting Jak2/STAT3 and IKK signaling pathways. Desmethoxyyangonin (Standard) induces CYP3A23 expression and leads to skeletal muscle relaxation ^[1] ^[2] .

HY-N1356A

(R)-Reticuline	Structural Classification Alkaloids Source classification Plants Lauraceae Isoquinoline Alkaloids Lindera aggregata (Sims) Kosterm.	Cytochrome P450
(R)-Reticuline is an isomer of Reticuline (HY-N1356). Reticuline displays anti-inflammatory and cardiovascular effects through JAK2/STAT3 and NF-κB signaling pathways. Salutaridine is a key intermediate in morphine biosynthesis. Salutaridine can be converted from (R)-Reticuline in the poppy plant. The conversion system relies on membrane-bound cytochrome P-450 enzymes and also requires reducing cofactors NADPH, molecular oxygen, etc ^[1] ^[2].

HY-N0678R

Icaritin (Standard) Anhydroicaritin (Standard)	Flavonols Structural Classification Human Gut Microbiota Metabolites Flavonoids Source classification Phenols Polyphenols Epimedium brevicornu Maxim. Plants Endogenous metabolite Berberidaceae	JAK Reference Standards Autophagy Apoptosis
Icaritin (Standard) is the analytical standard of Icaritin. This product is intended for research and analytical applications. Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 μM) and primary CML cells (IC₅₀ of 13.4 μM for CML-CP and 18 μM for CML-BC). Icaritin can regulate MAPK/ERK/JNK and JAK2/STAT3 /AKT signalings, also enhances osteogenesis ^[1] ^[2][3.

HY-N0201R

Atractylenolide I (Standard)	Structural Classification Terpenoids Sesquiterpenes Source classification Astragalus caprinus L. Plants Compositae	TNF Receptor Reference Standards Toll-like Receptor (TLR) JAK STAT
Atractylenolide I (Standard) is the analytical standard of Atractylenolide I. This product is intended for research and analytical applications. Atractylenolide I is a sesquiterpene derived from the rhizome of Atractylodes macrocephala, possesses diverse bioactivities, such as neuroprotective, anti-allergic, anti-inflammatory and anticancer properties. Atractylenolide I reduces protein levels of phosphorylated JAK2 and STAT3 in A375 cells, and acts as a TLR4-antagonizing agent.

HY-N0807

Swertiamarin	Structural Classification Monophenols other families Classification of Application Fields Phenols Zanthoxylum chiloperone var. angustifolium Metabolic Disease Plants Disease Research Fields Cancer	MMP NF-κB JAK Keap1-Nrf2
Swertiamarin is an orally active natural product with hypoglycemic, lipid-lowering, anti-rheumatic, and antioxidant activities. Swertiamarin can regulate the levels of pro-inflammatory cytokines, MMP, and NF-κB, and promote osteoblast proliferation. Swertiamarin has antioxidant and hepatoprotective effects against carbon tetrachloride induced rat liver toxicity through the *Nrf2/HO-1* pathway. Swertiamarin can attenuate inflammatory mediators by regulating *JAK2/STAT3* transcription factors in adjuvant induced arthritis rats. Swertiamarin can be used in the research of diabetes and arthritis ^[1] ^[2] ^[5].

HY-N2515

Ginsenoside Rk1 5+ Cited Publications	Panax ginseng C. A. Meyer Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields Araliaceae	NF-κB PI3K JAK Apoptosis
Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures ^[1]. Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of *Jak2/Stat3* signaling pathway and NF-κB ^[2]. Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis ^[1]. Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .

HY-N2515R

Ginsenoside Rk1 (Standard)	Panax ginseng C. A. Meyer Triterpenes Structural Classification Terpenoids Source classification Plants Araliaceae	Reference Standards NF-κB PI3K JAK Apoptosis
Ginsenoside Rk1 (Standard) is the analytical standard of Ginsenoside Rk1. This product is intended for research and analytical applications. Ginsenoside Rk1 is a unique component created by processing the ginseng plant (mainly Sung Ginseng, SG) at high temperatures ^[1]. Ginsenoside Rk1 has anti-inflammatory effect, suppresses the activation of Jak2/Stat3 signaling pathway and NF-κB ^[2]. Ginsenoside Rk1 has anti-tumor effect, antiplatelet aggregation activities, anti-insulin resistance, nephroprotective effect, antimicrobial effect, cognitive function enhancement, lipid accumulation reduction and prevents osteoporosis ^[1]. Ginsenoside Rk1 induces cell apoptosis by triggering intracellular reactive oxygen species (ROS) generation and blocking PI3K/Akt pathway .

HY-N0885

Telocinobufagin 1 Publications Verification Telobufotoxin; Telocinobufogenin	Structural Classification Animals Classification of Application Fields Source classification Other Diseases Disease Research Fields Steroids	JAK STAT mTOR PI3K Akt Polo-like Kinase (PLK) Na+/K+ ATPase Apoptosis Bacterial
Telocinobufagin (Telobufotoxin; Telocinobufogenin) is an orally active bufadienolide with potential anti-tumor effects. Telocinobufagin exerts its anti-cancer effects on non-small cell carcinoma, osteosarcoma, thyroid cancer, breast cancer and head and neck squamous cell carcinoma by inhibiting the STAT3, *JAK2/STAT3, LARP1-mTOR, PI3K/Akt/Snail* and *PLK1* pathways, and can also induce tumor cell apoptosis. Telocinobufagin enhances the Th1 immune response and protects against Salmonella typhimurium infection. Telocinobufagin has a strong cardiac-stimulating effect by inhibiting the activity of Na ⁺/K ⁺-ATPase, and it can promote renal fibrosis. Telocinobufagin demonstrates non-opioid analgesic effects in various acute pain models ^[1] ^[2] ^[5] .

HY-P2813

Hirudin 2 Publications Verification	Cardiovascular Disease Structural Classification Natural Products Animals Classification of Application Fields Source classification Disease Research Fields Cancer	Thrombin Apoptosis
Hirudin is a thrombin inhibitor with blood anticoagulant property. Hirudin has potent anti-thrombotic, wound repair, anti-fibrosis, anti-tumor and anti-hyperuricemia effects. Hirudin also affects diabetic complications, cerebral hemorrhage, and others ^[1].

Cat. No.	Product Name	Chemical Structure

HY-169326S

JAK2-IN-11
JAK2-IN-11 (Example 6) is a *JAK2* kinase inhibitor with IC₅₀ ≤10 nM against JH2 BIND WT/V617F. JAK2-IN-11 has antitumor activity ^[1].

HY-W062703S

(Rac)-Ruxolitinib-d9
(Rac)-Ruxolitinib D9 ((Rac)-INCB18424 D9) is the deuterium labeled (Rac)-Ruxolitinib. (Rac)-Ruxolitinib is a JAK2 inhibitor ^[1].

HY-16379S

Pacritinib-d4
Pacritinib-d₈ (SB1518-d₈) is the deuterium labeled Pacritinib (HY-16379). Pacritinib (SB1518) is a potent inhibitor of both wild-type *JAK2* (IC₅₀=23 nM) and JAK2 ^V617F mutant (IC₅₀=19 nM). Pacritinib also inhibits FLT3 (IC₅₀=22 nM) and its mutant FLT3 ^D835Y (IC₅₀=6 nM).

HY-50856S

Deuruxolitinib
Deuruxolitinib, a deuterated Ruxolitinib (HY-50856), is an orally active *JAK1* and *JAK2* inhibitor. Deuruxolitinib demonstrates significant hair regrowth effects. Deuruxolitinib can be used for the research of alopecia areata ^[1].

HY-15315S

Baricitinib-d5
Baricitinib-d₅ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-15315S1

Baricitinib-d3
Baricitinib-d₃ is the deuterium labeled Baricitinib. Baricitinib (LY3009104; INCB028050) is a selective and orally bioavailable JAK1 and JAK2 inhibitor with IC50s of 5.9 nM and 5.7 nM, respectively.

HY-161684

JAK2-IN-10
JAK2-IN-10 (compound 5) is a potent JAK2 V617F inhibitor with an IC₅₀ value of ≤10 nM ^[1].

HY-10409S

Fedratinib-d9

Fedratinib-d₉ (TG-101348-d₉) is deuterium labeled Fedratinib. Fedratinib (TG-101348) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC₅₀s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. Fedratinib induces cancer cell apoptosis and has the potential for myeloproliferative disorders research ^[1] ^[2] .

HY-18300S

Filgotinib-d4
Filgotinib-d₄ is the deuterium labeled Filgotinib. Filgotinib (GLPG0634) is a selective JAK1 inhibitor with IC50 of 10 nM, 28 nM, 810 nM, and 116 nM for JAK1, JAK2, JAK3, and TYK2, respectively.

HY-10961S8

Momelotinib-d4 dihydrochloride hydrate
Momelotinib-d₄ (CYT387-d₄) dihydrochloride hydrate is a deuterium labeled Momelotinib (HY-10961). Momelotinib (CYT387) is an ATP-competitive inhibitor of JAK1/JAK2 with IC₅₀s of 11 nM and 18 nM,respectively. CYT387 shows much less activity against JAK3 ^[1].

HY-126242S

Tyk2-IN-7

Tyk2-IN-7 is a TYK2 JH2 inhibitor, binds to TYK2 JH2 domain with IC₅₀ and K_i.app of 0.00053 μM and 0.00007 μM, respectively. Tyk2-IN-7 provides a highly selective alternative to conventional TYK2 orthosteric inhibitors, inhibits TYK2/JAK1/JAK2 kinase domain. Tyk2-IN-7 provides robust inhibition in a mouse IL-12-induced IFNγ pharmacodynamic model as well as efficacy in an IL-23 and IL-12-dependent mouse colitis model ^[1].

HY-W727879

Upadacitinib-15N,d2

1 Publications Verification

Upadacitinib- ¹⁵N,d₂ (ABT-494- ¹⁵N,d₂) is the deuterium-labeled Upadacitinib (HY-19569). Upadacitinib- ¹⁵N,d₂ (ABT-494) is a potent, orally active and selective Janus kinase 1 (JAK1) inhibitor (IC₅₀=43 nM). Upadacitinib- ¹⁵N,d₂ (ABT-494) displays approximately 74 fold selective for JAK1 over JAK2 (200 nM) in cellular assays dependent on specific, relevant cytokines. Upadacitinib- ¹⁵N,d₂ (ABT-494) can be used for several autoimmune disorders research ^[1] ^[2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks